Seeing double: Designing drugs that target twin cancer proteins Scripps Research scientists used knowledge about a protein to characterize drugs that selectively bind to its twin, or paralog.
September 30, 2024
LA JOLLA, CA Some proteins in the human body are easy to block with a drug; they have an obvious spot in their structure where a drug can fit, like a key in a lock. But other proteins are more difficult to target, with no clear drug-binding sites.
To design a drug that blocks a cancer-related protein, Scripps Research scientists took a hint from the protein's paralog, or twin. Using innovative chemical biology methods, the scientists pinpointed a druggable site on the paralog, and then used that knowledge to characterize drugs that bound to a similar but more difficult to detect spot on its twin. Ultimately, they found drugs that only bound to the protein of interest and not its highly similar sibling.
Their approach, described in Nature Chemical Biology on September 18, 2024, and dubbed paralog hopping, could uncover new binding sites for drugs and inform drug development more broadly, since nearly half of the proteins in human cells including many involved in cancer and autoimmune diseases have such paralogs.
This method may be generally useful in cases where you have paralogs, and you are trying to find a new drug for one of them, says senior author Benjamin Cravatt, PhD, the Norton B. Gilula Chair in Biology and Chemistry at Scripps Research. Being able to target one paralog over another is an important goal in drug development, as two paralogs often have different functions.
Many genes have duplicated throughout evolution, resulting in multiple copies in the human genome. In some cases, copies have evolved slightly different sequences from each other, making their corresponding proteins into paralogs. These protein paralogs remain highly similar in structure and often have redundant or overlapping functions within cells.
In recent years, Cravatt's research team formulated an approach to develop drugs that bind to the amino acid cysteine a protein building block with unique, highly reactive chemical properties. The scientists' method takes advantage of cysteines as an optimal site for drugs to attach to a protein permanently, often inactivating it. However, not all proteins have accessible cysteines. In the cases of paralog pairs, one protein may have a druggable cysteine that the other does not.
We started with this idea that if you know how to drug one protein, you can figure out how to drug its paralog in a similar way, says Yuanjin Zhang, a graduate student at Scripps Research and first author of the new paper.
As a test case, the team tackled the paralog pair known as CCNE1 and CCNE2. Both proteins have been found to be overactive in breast, ovarian and lung cancer. However, scientists suspected that the two proteins play slightly different roles. The team posited that turning off just one protein could make treating some cancers more effective.
It has been difficult, however, to design drugs that target the CCNE1 and CCNE2 proteins to test this hypothesis. Cravatt, Zhang and their colleagues knew that CCNE2 had a druggable cysteine, while CCNE1 did not. If they could identify drugs that bound to the same spot on CCNE1, even in the absence of a cysteine, they suspected the protein would shut off.
The scientists first engineered a cysteine into CCNE1, mimicking the drug-binding spot they had pinpointed in CCNE2. They then leveraged this neo-cysteine to identify drugs that bind to CCNE1. Next, they screened a library of other chemical compounds for the ability to compete with that drug in binding to CCNE1. The team reasoned that some of the compounds that competed for the same spot would bind in ways that did not rely on the cysteine.
Indeed, Cravatt, Zhang and their colleagues discovered multiple compounds that could bind to the same site on CCNE1 even when the cysteine was removed again. Some compounds did not bind to CCNE2. Some also had opposite functions, stabilizing the molecule so that it might be more active than usual, rather than inactivating it. Structural studies revealed that the CCNE1 compounds bind to a cryptic pocket that was not previously known to be druggable.
The team says the approach highlights the importance of screening for drugs in diverse, creative ways.
If we had just screened looking for compounds with a particular function, we would not have identified all of these various functional molecules, and if we had just looked at the structure of CCNE1, we would not have found this binding pocket at all, says Zhang.
More research is needed to discover whether the new compounds have potential utility in treating cancer or other diseases in which CCNE1 plays a role. Next, the scientists plan to apply their paralog-hopping method to other pairs of proteins important for tumorigenesis.
In addition to Cravatt and Zhang, authors of the study, An allosteric cyclin E-CDK2 site mapped by paralog hopping with covalent probes, include Zhonglin Liu, Sang Joon Won, Divya Bezwada and Bruno Melillo of Scripps Research; and Marsha Hirschi, Oleg Brodsky, Eric Johnson, Asako Nagata, Matthew D. Petroski, Jaimeen D. Majmudar, Sherry Niessen, Todd VanArsdale, Adam M. Gilbert, Matthew M. Hayward, Al E. Stewart and Andrew R. Nager of Pfizer, Inc.
This work was supported by funding from the National Cancer Institute (R35 CA231991) and Pfizer.
Chemistry Cravatt, Benjamin
Europe Stories
05/01/2027
Worlds first 802.15.4ab-UWB chip verified by Calterah and Rohde & Schwarz to be ...
04/08/2026
Dalet, a leading technology and service provider for media-rich organizations, t...
04/07/2026
April 7 2026, 19:00 (PDT) Detective Conan: Fallen Angel of the Highway Opens in...
01/06/2026
January 6 2026, 05:30 (PST) Dolby Sets the New Standard for Premium Entertainment at CES 2026
Throughout the week, Dolby brings to life the latest innovatio...
14/05/2026
At Spotify, we're focused on making every listening experience feel intentio...
14/05/2026
Spotify recently welcomed songwriters, artists, executives, and music students t...
14/05/2026
New articulations, ostinatos, Motion Scoring Articulation Sets & more
Sonuscore's flagship cinematic string library has just been treated to a significa...
14/05/2026
World-class studio opens on T rkiye's Aegean coast
P r Recording & Residence have announced their official opening, introducing a new world-class reside...
14/05/2026
Now supports channel layouts up to 9.1.6
Nugen Audio have just released an update for their AI-powered dialogue intelligibility and compliance tool. Set to ...
14/05/2026
New recordings & one-key chord tool
UVI have just announced the release of Orchestral Suite 2, a ground-up redesign of their all-in-one symphonic orchestra ...
14/05/2026
Two new arrivals & expanded factory content
Rob Papen's all-encompassing plug-in and virtual instrument collection has just been treated to another upda...
14/05/2026
Embed QR codes into DAW sessions
FSK Audio's latest plug-in doesn't process audio, but serves as an organisational tool that allows QR codes to be e...
14/05/2026
Rohde & Schwarz transforms spectrum complexity into situational awareness and ef...
14/05/2026
Rohde & Schwarz and Quantum Systems join forces to redefine EW and C-UAS-enabled...
14/05/2026
Rohde & Schwarz showcases STANAG aligned ARDRONIS Counter UAS capability at NATO...
14/05/2026
Code of Silence has won the BAFTA for Best Drama Series at Sunday night's ceremony at the Royal Festival Hall.
The series, starring Rose Ayling-Ellis and w...
14/05/2026
Vivid Broadcast was embracing remote production long before it became the industry norm. Now, with Calrec's True Control 2.0-enabled Argo M and Type R conso...
14/05/2026
What can I watch on UKTV and stream on U this week?
This week on UKTV and the free streaming service U, viewers can watch a range of new and returning programm...
14/05/2026
The high-stakes chase thriller from Oscar- and BAFTA-nominated writer Matt Charm...
14/05/2026
Back From The Brink airs Sunday 17 May and Sunday 24 May at 6.30pm on RT One an...
13/05/2026
13 May 2026
VEON Delivers Strong Start to 2026 1Q26: Revenue 17.0%, EBITDA 17...
13/05/2026
Thousands of props donated from Skys longest-running original seriesWednesday 13 May 2026
How a neon windmill from A League of Their Own ended up in a dogs'...
13/05/2026
SAN JOSE, Calif. - May 13, 2026 - Harmonic (NASDAQ: HLIT) today announced that I...
13/05/2026
A definitive portrait of one of Ireland's most influential musicians
New TV documentary airs Monday 18 May on RT One and RT Player at 9.35pm
Watch the...
12/05/2026
Spotify is where fans and artists come together, turning discovery into somethin...
12/05/2026
Features patented Marco-MMC clocking technology
Black Lion Audio's latest release combines the company's expertise in clocking with their renowned p...
12/05/2026
New Track Panel, sequencer upgrades & more
Following their recent public beta release, Reason Studios have announced the full release of Reason 14. With the...
12/05/2026
Rohde & Schwarz presents its advanced solutions for power electronics testing at...
12/05/2026
aconnic AG (ISIN: DE000A0LBKW6), Munich, has developed a modified fund raising p...
12/05/2026
FOX Announces Schedule for 2026-27 Season FOX'S POWERFUL NEW SERIES PIPELINE FUELS A BREAKOUT SEASON WITH RETURNING HITS AND BOLD NEW STORYTELLING ACROSS ...
12/05/2026
Customer demand for data continues to grow in the first quarter of 2026 at Magya...
12/05/2026
The latest drama underscores Sky's continued investment in regional production and Welsh creative talent.Tuesday 12 May 2026
Wales takes the spotlight in S...
11/05/2026
As Eurovision fans gear up to celebrate the 70th anniversary of the iconic song ...
11/05/2026
Pela primeira vez na hist ria, o Brasil figura entre os oito maiores mercados de...
11/05/2026
New desktop instrument focused on tactile performance
Bastl Instruments have announced the Kalimba, a new desktop instrument that combines physical modellin...
11/05/2026
Compact sampling workstation gains new features
1010music have announced the blackbox 2, a new version of their compact standalone sampler designed for DAWl...
11/05/2026
Performance-focused sequencer with microtonal control
Berlin-based KOMA Elektronik have announced Monoplex, a new 42HP Eurorack sequencer designed for hands...
11/05/2026
Boasts wireless control from mobile devices
The latest iteration of IK Multimedia's compact amp and effects modelling pedal expands on the capabilities ...
11/05/2026
Spans traditional orchestral and experimental sounds
Sonora Cinematic have recently released the third instalment in their Transfigured Orchestra series, de...
11/05/2026
Our exhibition coverage
Watch all our SUPERBOOTH 2026 video coverage in one place. Check back to this page regularly as we will be updating with more video ...
11/05/2026
aconnic AG (ISIN: DE000A0LBKW6), Munich, is participating in the Equity Forum Ge...
11/05/2026
Bounteous Acquires Cartesian to Accelerate Enterprise AI
May 11, 2026
Business Assurance
News
Acquisition enhances deep data and analytics capabil...
11/05/2026
11 May 2026
VEON Shareholders Re-elect Board and Chairman, Reaffirming Confiden...
11/05/2026
Fox Corporation Reports Third Quarter Fiscal 2026 Financial Results NEW YORK, NY, May 11, 2026 - Fox Corporation (Nasdaq: FOXA, FOX; FOX or the Company ) t...
11/05/2026
Arvato Systems Becomes a Member of InsurLab Germany
Collaboration in the insurance industrys leading innovation network
G tersloh - Arvato Systems has joine...
11/05/2026
Pirate Predator uncovers new information from victims and survivors of abuse on ...
10/05/2026
RT ALL-IRELAND DRAMA FESTIVAL WINNERS ANNOUNCED DURING GALA AWARDS STREAMED LIVE ON RTE.IE/CULTURE
Kilmeen Drama Group hailing from Rossmore, Co. Cork Scoops ...
09/05/2026
New desktop instrument focused on tactile performance
Bastl Instruments have announced Kalimba, a new desktop instrument that combines physical modelling, F...
09/05/2026
Compact sampling workstation gains new features
1010music have announced blackbox 2, a new version of their compact standalone sampler designed for DAWless ...
Seeing double: Designing drugs that target twin cancer proteins Scripps Research scientists used knowledge about a protein to characterize drugs that selectively bind to its twin, or paralog.
